News

September 21, 2018

Voluntis, AstraZeneca to Test Mobile App Supporting Patients with Platinum-Resistant Ovarian Cancer

News

Voluntis and AstraZeneca have extended their partnership to evaluate a mobile app, called eCO (eCediranib/Olaparib), to help women with platinum-resistant ovarian cancer report and manage their side effects. The approach is being developed ... Read more

September 19, 2018

Upcoming Phase 2 Trial to Evaluate DPX-Survivac with Keytruda in Ovarian, Other Solid Tumors

News

IMV will soon launch a Phase 2 trial to examine the potential of its lead candidate DPX-Survivac in combination with Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in five solid tumor types. The study is ... Read more

September 17, 2018

Two-pronged Antibody Can Help Efficiently Destroy Ovarian Cancer Cells, Researchers Find

News

A newly developed two-pronged antibody is 100 times more effective at destroying ovarian cancer cells than other antibodies in clinical trials, according to researchers at the University of Virginia ... Read more

September 14, 2018

Celsion Doses First Ovarian Cancer Patient in Phase 1/2 Trial of GEN-1

News

The Phase 1/2 trial evaluating Celsion’s investigational DNA-based immunotherapy GEN-1 as an add-on to standard chemotherapy for localized treatment of ovarian cancer has started dosing patients. GEN-1 is a nanoparticle containing the ... Read more

September 12, 2018

IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient

News

The Phase 1b/2 trial investigating IMV lead candidate DPX-Survivac in combination with Incyte‘s experimental epacadostat and low-dose chemotherapy in recurrent ovarian cancer patients has completed patient enrollment in the study’s first part, ... Read more

September 10, 2018

Ovarian Cancer Cells Retain Iron to Fuel Growth, Research Suggests

News

Iron accumulation, a well-known feature of ovarian cancer cells, may play a role in cancer progression by increasing fatty acid metabolism, researchers at UConn Health suggest. Their study, “A Systems Biology Approach ... Read more

September 7, 2018

Sorafenib plus Hycamtin Combo Prolongs Survival in Platinum-resistant Ovarian Cancer, Phase 2 Trial Shows

News

Adding sorafenib, an anti-cancer oral medicine, to Hycamtin (topotecan) chemotherapy slows the time to disease progression or death in women with platinum-resistant ovarian cancer, a Phase 2 trial shows. ... Read more

September 5, 2018

Algorithm Predicts Response to Measles Virus Therapy in Ovarian, Other Cancers, Study Shows

News

Researchers at the Mayo Clinic developed an algorithm to predict the response of ovarian cancer patients to measles virus therapy, an investigational anti-cancer treatment being developed by the large U.S.-based ... Read more

August 29, 2018August 29, 2018

FDA OKs Phase 2 Trial Evaluating 2X-121 in Advanced Ovarian Cancer Patients

News

The U.S. Food and Drug Administration has green-lighted a Phase 2 clinical trial that will assess the safety and effectiveness of the small molecule 2X-121 in advanced ovarian cancer patients, Oncology ... Read more

August 22, 2018August 22, 2018

Aravive Biologics’ Therapy Earns FDA’s Fast Track Designation to Treat Advanced Ovarian Cancer

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to AVB-S6-500 as a potential therapy for chemotherapy-resistant ovarian cancer, Aravive Biologics, the therapy’s developer, announced. Fast track designation is ... Read more

Pin It on Pinterest